10 / July / 2026 Cancer treatments advance, but clinical trials lack diversity Most drugs are tested on populations from wealthy countries—expanding participation to other regions could make therapies more effective for different patient profiles By Gabriela Monteiro
01 / July / 2026 El Niño 2026 raises concerns in Brazil Technical note predicts a high likelihood of the phenomenon developing in the second semester, putting extreme heat, droughts, flooding, and Brazil’s public health preparedness in the spotlight. By Bruno de Pierro
23 / June / 2026 Deprescribing: a growing trend in elderly care Recent studies examine when discontinuing antihypertensives, statins, and other medications may reduce risks for elderly, frail, or polymedicated patients By Samuel Antenor
18 / June / 2026 Experimental drug reduces risk of second stroke by 26% International clinical trial involving Brazilian researchers tested asundexian in patients following ischemic stroke By Gilberto Stam
16 / June / 2026 Electroacupuncture may help treat chemotherapy-induced pain Phase 3 study presented at the ASCO Annual Meeting evaluates the technique as a nonpharmacological alternative for peripheral neuropathy in cancer patients By Samuel Antenor
12 / June / 2026 “An endangered species”: what is driving physician-scientists out of science? Survey of 230 US professionals finds that 49% are considering leaving research, for reasons beyond lack of funding By Gilberto Stam
10 / June / 2026 Cancer clinical trials grow more slowly than expected in Brazil, study finds A 20-year analysis shows that the country has made progress but still faces regulatory and cultural barriers, as well as reliance on the pharmaceutical industry. By Gabriela Monteiro
09 / June / 2026 Butantan dengue vaccine: why rigorous testing cannot predict all rare effects After precautionary suspension by the Ministry of Health, Einstein researcher explains how randomized clinical trials and post-approval surveillance work By Editorial staff
04 / June / 2026 Frontier science takes risk, but Brazil still punishes failure Experts say that truly innovative projects require safer environments in which to make mistakes, recombine knowledge, and challenge paradigms By Daniel Dieb
02 / June / 2026 Pancreatic cancer: Oral drug almost doubles survival in clinical trial Data presented at ASCO 2026 showed that daraxonrasib reduced the risk of death by 60% in patients with metastatic pancreatic cancer By Daniel Dieb
